Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director · President and CEO | February 01, 2023 | February 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 01, 2023 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 216,500 |
Reported balance
After 2023-02-01 transaction · row 1
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 216,500 · Balance 216,500 F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2033-02-01 | Direct | 866,000 |
Reported balance
After 2023-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-01 · Grant · Acquired 866,000 · Balance 866,000 F2: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 3, 2023 21:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 866,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001447028-23-000008 · wf-form4_167545861445606.xml · derivative · entry 2 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,000 Underlying: Common Shares · 866,000 shares Expires 2033-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 216,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-23-000008 · wf-form4_167545861445606.xml · nonDerivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 22:55 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 787,550 | $2.81 Strike: $2.81 | $2,213,015.50 |
DisclosureSEC source: 0001447028-22-000012 · wf-form4_164271931496383.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787,550 Underlying: Common Shares · 787,550 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 22:00 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 675,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000010 · wf-form4_161359921500159.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 20:05 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000143 · wf-form4_160106428541454.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the performance based option grant was approved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to both shareholder approval of an amendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment") and the fulfillment of certain performance criteria. F2 · derivative.exercise_date: The Registrant's shareholders approved the Plan Amendment on May 28, 2020. On September 23, 2020, the Committee determined that the performance criteria had been met. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:02 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 262,313 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000067 · wf-form4_159104531419172.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,313 Underlying: Common Stock · 262,313 shares Expires 2030-02-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the option grant was approved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to shareholder approval of an amendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment"). F2 · date: The option grant was approved by the Committee on February 17, 2020, subject to shareholder approval of the Plan Amendment. The Registrant's shareholders approved the Plan Amendment on May 28, 2020. F3 · derivative.exercise_date: The stock option will vest and become exercisable as to 3/48ths of the common shares on the grant date and an additional 1/48th of the total original common shares on the 17th day of each of the next 45 months. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:04 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 367,087 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000028 · wf-form4_158211745366536.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,087 Underlying: Common Stock · 367,087 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:18 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,112,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001123292-19-000911 · edgar.xml · derivative · entry 1 Collier William H. · CIK 0001780495 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,000 Underlying: Common Shares · 1,112,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 25% of the common shares on June 24, 2020 and as to an additional 1/48th of the total original number of common shares subject to Mr. Collier's stock option on the corresponding day of each month over the three year period thereafter, subject to Mr. Collier's continued employment with Arbutus Biopharma Corporation through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.